Navigation Links
Lialda® (Mesalamine) Now Approved in U.S. for Maintenance of Remission of Ulcerative Colitis
Date:7/18/2011

using the comparator, mesalamine delayed-release 1.6 g/day (n=336) administered as 0.8 g given twice daily (81.5%, 95% confidence interval for difference: -3.9%, 8.1%).

Safety of Lialda in the maintenance of remission of ulcerative colitis was evaluated in three studies, one being a six-month, double-blind, non-inferiority, comparator study and two being 12- to 14-month open-label studies. The most common adverse reactions with Lialda in the maintenance arms of these three trials were ulcerative colitis, headache, abnormal liver function test and abdominal pain. The most common severe adverse reactions were gastrointestinal disorders, most of which are consistent with symptoms associated with ulcerative colitis.

In 2007, Lialda gained FDA approval for the induction of remission in patients with active, mild to moderate ulcerative colitis as a result of two eight-week, placebo-controlled clinical studies demonstrating safety and effectiveness.

Important Safety InformationYou should not take Lialda if you are allergic to salicylates (including mesalamine, aspirin, or aspirin-containing products) or to any of the ingredients of Lialda.  

Reports of problems with kidney function have been associated with mesalamine-containing products like Lialda. Tell your doctor if you have or have had problems with your kidneys. It is recommended that all patients have their kidney function checked before starting Lialda and periodically while on therapy.

Products that contain mesalamine, like Lialda, have been associated with a condition that may be difficult to distinguish from an ulcerative colitis flare-up. Symptoms include cramping, stomach ache, bloody diarrhea, fever, headache, and rash. If you experience any of these symptoms, talk to your doctor immediately. Your doctor may decide to discontinue your medication.  

Tell your doctor if you are allergic to sulfasalazine, as you may also be allergic to Lialda or drugs that
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
2. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
3. Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis
4. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
5. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
6. Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets
7. Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting
8. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
9. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
10. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
11. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  Medela announced today ... Biomedical Company (ABC), assigning Medela as the exclusive distributor ... known as the Medela Enteral Feeding Pump. Through this ... help NICU parents and healthcare professionals by offering a ... Medela Enteral Feeding Pump is integral to the delivery ...
(Date:9/23/2014)... Sept. 23, 2014 A case report and ... SynCardia temporary Total Artificial Heart into a patient with ... were reversed, along with other abnormalities. ... the SynCardia Total Artificial Heart to treat a patient ... and video in the Journal of Visualized Experiments show ...
(Date:9/23/2014)... September 23, 2014 BerGenBio ... company, today announces it has been granted a ... Award from the UK,s Wellcome Trust to develop ... novel cancer target. The Wellcome Trust ... fund especially promising, innovative new therapeutic concepts through ...
Breaking Medicine Technology:Medela Enters Exclusive Enteral Feeding Pump Agreement with Atlanta Biomedical Company 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 31st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 4BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 2BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 3
... SYDNEY, Sept. 15 HeartWare International, Inc. (Nasdaq: ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... CEO Doug Godshall is scheduled to make an investor ... on Tuesday, September 21, at 12:30 pm EDT.  The ...
... Md., Sept. 15 The U.S. Food and Drug ... recommendations for Valcyte (valganciclovir) oral tablets and solution used ... transplant. The update is intended to prevent drug overdosing ... area, and very low serum creatinine. The revised dosing ...
Cached Medicine Technology:HeartWare to Present at the UBS 2010 Global Life Sciences Conference 2FDA Issues New Dosing Guide for Children Using Valcyte 2
(Date:9/23/2014)... If you or a loved one ... treatment may be a challenge. Fortunately, an inventor from ... is designed to improve the experience. , He developed ... having to remove, tear or reposition their clothing. Furthermore, ... their dignity. At the same time, it safeguards their ...
(Date:9/23/2014)... been shown to be a driving force behind ... develops due to chronic inflammation caused by conditions ... relatively few effective treatment options. Now, scientists at ... for the first time in preclinical studies that ... astrocyte elevated gene-1 (AEG-1) halts the development and ...
(Date:9/23/2014)... Becker's Hospital Review has published ... Hospitals and Health Systems With Great Orthopedic Programs." ... the list have orthopedic surgery departments, programs or ... reputable sources. Exceptional orthopedic departments include physicians who ... and treat professional athletes. , This is the ...
(Date:9/23/2014)... the curve of oxygen desaturation" (AUC Desat ) may ... levels during procedures using sedation, according to a study ... AUC Desat provides information not only whether blood ... duration, and rate of episodes of oxygen desaturation. ... of Cincinnati and colleagues reports on the development of ...
(Date:9/23/2014)... Contrary to what is often assumed about single parents, ... from The Kinsey Institute has found that single parents ... active as often as singles without children -- and ... The study, "Dating and Sexual Behavior Among Single Parents ... online in the Journal of Sex Research ...
Breaking Medicine News(10 mins):Health News:Apparel for Dialysis Patients Invented by InventHelp Client (CBA-2492) 2Health News:Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer 2Health News:125 Hospitals With Great Orthopedic Programs 2Health News:125 Hospitals With Great Orthopedic Programs 3Health News:125 Hospitals With Great Orthopedic Programs 4Health News:125 Hospitals With Great Orthopedic Programs 5Health News:New measure provides more data on oxygen levels during sedation 2Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2
... WASHINGTON, Aug. 9 SEIU ... wherever they occur. We are ... been raised concerning SEIU Local ... Union, and will take any ...
... fade after first injection, so second shot now recommended , , ... chickenpox was introduced in the United States in 1995, medical ... single injection about the time of a child,s first birthday ... so. They,ve found that the protection from a single immunization ...
... Responding to increased concerns about the health hazards ... employed the use of the Mini C-Arm throughout ... week are bringing this advanced technology to their ... patient care, Nighttime Care Centers have introduced the ...
... of Miley Cyrus and,the Jonas Brothers will have more ... artists take the stage with other performers at Disney,s,Concert ... programs at City of Hope. It will be held ... Tickets for the concert will,be available Saturday, August 16 ...
... PD-Rx Pharmaceuticals,Inc., a publicly held corporation, (Pink Sheets: ... of all of its outstanding Preferred "A",stock., ... Cumulative,Convertible Stock representing One Hundred and Sixty Five ... Inc. The,stock call represents PD-Rx,s position to improve ...
... Aug. 8 /PRNewswire/ - IntelliPharmaCeutics is pleased to,provide ... press release to,the Company, include IntelliPharmaCeutics Ltd. and ... been very active with drug development work at ... Toronto, Canada. We,presently have 34 staff employed full-time ...
Cached Medicine News:Health News:Chickenpox Protection: Get That Booster 2Health News:Chickenpox Protection: Get That Booster 3Health News:Nighttime Care Centers Introduce Mini C-Arm Mobile X-Ray Technology to Anne Arundel County 2Health News:Nighttime Care Centers Introduce Mini C-Arm Mobile X-Ray Technology to Anne Arundel County 3Health News:The Walt Disney Company Is Presenting Miley Cyrus, Jonas Brothers and Demi Lovato in a Special Concert to Benefit City of Hope on September 14 2Health News:The Walt Disney Company Is Presenting Miley Cyrus, Jonas Brothers and Demi Lovato in a Special Concert to Benefit City of Hope on September 14 3Health News:PD-Rx Completes Call for Preferred A Stock 2Health News:IntelliPharmaCeutics Provides Update on Activities 2Health News:IntelliPharmaCeutics Provides Update on Activities 3Health News:IntelliPharmaCeutics Provides Update on Activities 4
... for the Humphrey Field Analyzer, SITA ... shows less inter-test variability than Full ... of reproducibility as Full Threshold SWAP. ... with the earlier glaucoma damage detected ...
... you can trust its capabilities will ... cataract, and glaucoma therapy in one ... is the optimal system for photocoagulation, ... iridotomy. The push of a button ...
... The VISUCAM non-mydriatic ... quality and simplicity of ... big enough to set ... photography, it features a ...
... YAG III is the new disruption ... in particular for applications in posterior ... the YAG laser is also used ... IOL polishing. It's another milestone in ...
Medicine Products: